Grant
US health agency funds broad access trial for Melbourne biotech's ALS drug
America's NIH has agreed to fund a program giving up to 200 ALS patients access to Neurizon Therapeutics' drug NUZ-001, with Melbourne-based Neurizon as subawardee and a Boston ALS centre running it.